Rapid Identification of Dihydropyrimidine Dehydrogenase Deficiency by Using a Novel 2-13C-Uracil Breath Test

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Cancer Research

• Publication date

  2004-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-03-0374PMID 15102667
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.

  2003cited by this paper
• Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.

  2003cited by this paper
• Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer

  2003cited by this paper
• A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms.

  2002cited by this paper
• A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency.

  2002cited by this paper
• Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.

  2002cited by this paper
• Screening and diagnosis of beta-ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urine.

  2002cited by this paper
• Increased risk of grade IV neutropenia after administration of 5‐fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutation

  2002cited by this paper
• Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

  2001cited by this paper
• C Mixed Triglyceride Breath Test: A Noninvasive Method to Assess Lipase Activity in Children

  2001cited by this paper
• Simple gas chromatographic-mass spectrometric procedure for diagnosing pyrimidine degradation defects for prevention of severe anticancer side effects.

  2001cited by this paper
• Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil.

  2001cited by this paper
• 13 C Mixed Triglyceride Breath Test: A Noninvasive Method to Assess Lipase Activity in Children

  2001cited by this paper
• 13C-egg white breath test: a non-invasive test of pancreatic trypsin activity in the small intestine

  2000cited by this paper
• Comparison of an enzyme immunoassay for the detection ofHelicobacter pylori antigens in the faeces with the urea breath test

  2000cited by this paper
• Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.

  2000cited by this paper
• Accuracy of an enzyme immunoassay for the detection of Helicobacter pylori in stool specimens in the diagnosis of infection and posttreatment check-up

  2000cited by this paper
• Known variant DPYD alleles do not explain DPD deficiency in cancer patients.

  2000cited by this paper
• Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.

  1999cited by this paper
• Population and family studies of dihydropyrimidinuria: prevalence, inheritance mode, and risk of fluorouracil toxicity.

  1998cited by this paper
• Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

  1998cited by this paper
• Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

  1998cited by this paper
• Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.

  1998cited by this paper
• Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity.

  1997cited by this paper
• Human Polymorphism in Drug Metabolism: Mutation in the Dihydropyrimidine Dehydrogenase Gene Results in Exon Skipping and Thymine Uracilurea

  1995cited by this paper
• Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes.

  1995cited by this paper
• (13)C-breath tests to measure fat and carbohydrate digestion in clinical practice.

  1995cited by this paper
• Population study of dihydropyrimidine dehydrogenase in cancer patients.

  1994cited by this paper
• [Population study of dihydropyrimidine dehydrogenase in cancer patients].

  1994cited by this paper
• 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo.

  1993cited by this paper
• Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.

  1993cited by this paper
• Sample size determination for bioequivalence assessment by means of confidence intervals.

  1992cited by this paper
• Sample size determination for bioequivalence assessment by means of confidence intervals.

  1991cited by this paper
• Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion.

  1990cited by this paper
• Power of the two one-sided tests procedure in bioequivalence

  1990cited by this paper
• Starch digestion in normal subjects and patients with pancreatic disease, using a 13CO2 breath test.

  1989cited by this paper
• Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.

  1988cited by this paper
• Enzymes of uracil catabolism in normal and neoplastic human tissues.

  1985cited by this paper

• Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review

  2022cites this paper
• Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy

  2022cites this paper
• European guideline on indications, performance and clinical impact of ¹³Câ•’breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC

  2021cites this paper
• Cytogenetic and Biochemical Genetic Techniques for Personalized Drug Therapy in Europe

  2021cites this paper
• European guideline on indications, performance and clinical impact of 13C‐breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC

  2021cites this paper
• Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?

  2020cites this paper
• A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants.

  2020cites this paper
• A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment

  2020influential citation
• Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines

  2019cites this paper
• Structure Function Relationships in Pyrimidine Degrading and Biocatalytic Enzymes, and Their Implications for Cancer Therapy and Green Chemistry

  2018cites this paper
• Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy

  2018cites this paper
• Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients

  2018cites this paper
• Polymorphisms in Pharmacogenetics of Personalized Cancer Therapy

  2017cites this paper
• Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.

  2017cites this paper
• Management of 5-fluorouracil treatment using Therapeutic drug monitoring (TDM)

  2017cites this paper
• “Dial Up and Lock In”: Asymmetric Organo-Brønsted Acid Catalysis Incorporating Stable Isotopes

  2016cites this paper
• Towards a test to predict 5-fluorouracil toxicity: Pharmacokinetic data for thymine and two sequential metabolites following oral thymine administration to healthy adult males.

  2016cites this paper
• Therapeutic drug monitoring of 5-fluorouracil

  2016cites this paper
• Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.

  2016cites this paper
• Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?

  2016cites this paper
• Costs and effectiveness of genomic testing in the management of colorectal cancer.

  2015cites this paper
• Pharmacogénétique des analogues nucléosidiques : Cytidine déaminase et issue clinique

  2015cites this paper
• Further characterization of a 13C-dextromethorphan breath test for CYP2D6 phenotyping in breast cancer patients on tamoxifen therapy

  2015cites this paper
• Correlation between dihydropyrimidine dehydrogenase and efficacy and toxicity of fluoropyrimidine drugs.

  2014cites this paper
• XELOX+Bevacizumab投与により重篤な有害事象を来したdihydropyrimidine dehydrogrnase欠損症の1例

  2014cites this paper
• 2-13C-Uracil 呼気テストによるS-1 感受性予測

  2014cites this paper
• An osteogenesis imperfecta case with breast cancer

  2014cites this paper
• La dihydropyrimidine déshydrogénase (DPD)

  2014cites this paper
• 5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice.

  2014cites this paper
• Regulatory issues on breath tests and updates of recent advances on [13C]-breath tests

  2013cites this paper
• Breath Tests to Phenotype Drug Disposition in Oncology

  2013cites this paper
• Indirect assessment of dihydropyrimidine dehydrogenase activity in cats.

  2013cites this paper
• Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.

  2013cites this paper
• Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity

  2013cites this paper
• Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency

  2013cites this paper
• Screening for dihydropyrimidine dehydrogenase deficiency to prevent severe 5-fluorouracil and capeciatbine-associated toxicity

  2013cites this paper
• Zastosowanie izotopowych testów oddechowych w diagnostyce przewodu pokarmowego

  2013cites this paper
• A Rapid Non Invasive L-DOPA-13C Breath Test for Optimally Suppressing Extracerebral AADC Enzyme Activity - Toward Individualizing Carbidopa Therapy in Parkinson's Disease

  2012cites this paper
• Substrate/Product-targeted NMR monitoring of pyrimidine catabolism and its inhibition by a clinical drug.

  2012cites this paper
• Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy

  2012cites this paper
• Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5‐fluorouracil–based chemotherapy

  2012cites this paper
• 13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients

  2012cites this paper
• Let's get personal: predicting thiopurine and fluoropyrimidine toxicity.

  2012cites this paper
• Tegafur–uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle

  2012cites this paper
• A Rapid HPLC-ESI-MS/MS Method for Determination of Dihydrouracil/Uracil Ratio in Plasma: Evaluation of Toxicity to 5-Flurouracil in Patients With Gastrointestinal Cancer

  2012cites this paper
• Current trends in the chemotherapy of colorectal cancer.

  2012cites this paper
• Analytical methods based on exhaled breath for early detection of lung cancer

  2012cites this paper
• Gastric cancer: Classification, histology and application of molecular pathology.

  2012cites this paper
• Phenotype Breath Tests as Companion Diagnostic Tests (CDx) in Clinical Trials of Drugs

  2012cites this paper
• 13C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients

  2012cites this paper
• Dermatologic Presentations of Orthopedic Pathologies

  2012cites this paper
• Basal Cell Carcinoma

  2012cites this paper
• Assessment of plasma uracil-to-dihydrouracil concentration ratio as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency.

  2012cites this paper
• Carbon-13 and Its Clinical Application

  2011cites this paper
• Translational research into oral colon-specific drug delivery

  2011cites this paper
• The role of mathematical modeling in VOC analysis using isoprene as a prototypic example

  2011cites this paper
• Lung cancer biomarkers in exhaled breath

  2011cites this paper
• Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency

  2011cites this paper
• Management of capecitabine-related gastrointestinal toxicities in women with breast cancer

  2011cites this paper
• Synthesis and purification of [2‐13C]‐5‐fluorouracil

  2011cites this paper
• Pruebas de aliento basadas en sustratos marcados con carbono 13 Breath test based on substrates labeled with carbon 13

  2011cites this paper
• Determinants of antifolate and 5-fluorouracil efficacy

  2011cites this paper
• Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography–tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity

  2011cites this paper
• Applications of stable isotopes in clinical pharmacology.

  2011cites this paper
• Clinically relevant genetic variations in drug metabolizing enzymes.

  2011cites this paper
• Breath biomarkers for personalized medicine.

  2010cites this paper
• Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity

  2010cites this paper
• Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?

  2010cites this paper
• Toxicité sévère à la capécitabine liée à un déficit enzymatique en dihydropyrimidine déshydrogénase (DPD)

  2010cites this paper
• Single time point diagnostic breath tests: a review

  2010cites this paper
• [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].

  2010cites this paper
• Future Advances in Cancer Pharmacogenomics

  2010cites this paper
• Linkage between Toxicology of Drugs and Metabolism

  2010cites this paper
• A novel and specific fluorescence reaction for uracil.

  2010cites this paper
• Can the 2-13C-uracil breath test be used to predict the effect of the antitumor drug S-1?

  2010cites this paper
• Analysis of exhaled breath for screening of lung cancer patients

  2010cites this paper
• [Recent developments of pharmacogenomics in the treatment of colorectal cancers].

  2010cites this paper
• 13C breath tests in personalized medicine: fiction or reality?

  2009cites this paper
• Chemotherapy in the Pediatric Patient

  2009cites this paper
• Rapid Identification of the Hepatic Cytochrome P450 2C19 Activity Using a Novel and Noninvasive [13C]Pantoprazole Breath Test

  2009influential citation
• Rapid identification of the hepatic cytochrome P450 (CYP) 2C19 activity using a novel and noninvasive [13C]-pantoprazole breath test

  2009cites this paper
• Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.

  2009cites this paper
• 13C-5-FU breath test current status and future directions: a comprehensive review

  2009cites this paper
• Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment

  2009cites this paper
• Unanticipated toxicity to capecitabine.

  2009cites this paper
• Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3)

  2009cites this paper
• Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?

  2009cites this paper
• Capecitabine: an overview of the side effects and their management

  2008cites this paper
• Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene

  2008cites this paper
• Genetic regulation of &bgr;-ureidopropionase and its possible implication in altered uracil catabolism

  2008cites this paper
• Predicting fluorouracil toxicity: can we finally do it?

  2008cites this paper
• Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review.

  2008cites this paper
• Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients

  2008cites this paper
• Part II: Liver function in oncology: towards safer chemotherapy use.

  2008cites this paper
• Dihydropyrimidine Dehydrogenase (Dpyd) Gene Polymorphism: Portrait of a Serial Killer

  2008cites this paper
• Phenotype breath tests for personalized medicine

  2007cites this paper
• A simple non-invasive method to detect and monitor hypercapnia: the sodium [13C]bicarbonate breath test

  2007cites this paper
• DPYD*2A mutation: the most common mutation associated with DPD deficiency

  2007cites this paper
• 13C-breath tests: current state of the art and future directions.

  2007cites this paper
• Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism

  2007cites this paper